# A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

> **NCT06561685** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 340 (estimated)

## Conditions studied

- Metastatic Solid Tumor
- Advanced Solid Tumor
- Non-small Cell Lung Cancer
- SMARCA4-Deficient Tumor

## Interventions

- **DRUG:** LY4050784
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT06561685
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561685, "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06561685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*